Polpharma Biologics has filed for approval in the EU for its biosimilar of Tysabri, Biogen’s multiple sclerosis (MS) therapy. The application is the first of its kind in the EU, and covers the intravenous version of the drug. Biogen originally had 5 more years of exclusivity, but a key patent for […]
Tralokinumab Improves Quality of Life for Teens with Atopic Dermatitis
New data released from Leo Pharma indicates that their biologic drug tralokinumab-ldrm improved quality of life, anxiety, itching, depression and sleep disturbances for teens with atopic dermatitis between 12-17 years of age. The results, presented at the Western Society of Allergy, Asthma & […]
